What Is the Prostate? Location, Function & Conditions

The prostate is a small, walnut-sized gland found only in people assigned male at birth, nestled just below the bladder and in front of the rectum. Its primary job is producing a portion of the fluid that makes up semen, but it sits at a crossroads of the urinary and reproductive systems in a way that makes it prone to several common conditions as men age. Understanding where the prostate is, what it does, and what can go wrong with it helps make sense of everything from routine screening conversations to treatment decisions.

Location and Zonal Anatomy

The prostate wraps around the urethra, the tube that carries urine out of the bladder. This positioning explains why prostate problems so often cause urinary symptoms: when the gland swells, it squeezes the very channel you urinate through. It sits just in front of the rectum, which is why a doctor can feel its surface during a digital rectal exam.

Internally, the prostate is not a uniform blob of tissue. In the 1960s, a pathologist named John McNeal proposed dividing it into distinct zones, and that framework is still used today. The three main zones are the peripheral zone, the transition zone, and the central zone. Each behaves differently when it comes to disease. The peripheral zone makes up the bulk of glandular tissue and is where most prostate cancers originate. The transition zone, which surrounds the urethra, is where benign enlargement tends to occur. The central zone sits at the base of the prostate near the seminal vesicles and is the least commonly affected by either cancer or benign growth.¹

These zonal differences are not just anatomical trivia. Cancers arising in the transition zone tend to behave differently from those in the peripheral zone. One study found that transition-zone cancers, despite being associated with higher PSA levels and larger tumor volumes, had lower odds of spreading beyond the gland and a lower hazard of recurrence after surgery compared with peripheral-zone cancers.² In practical terms, the zone where a tumor sits can influence how aggressive it is and how it is managed.

What the Prostate Does

The prostate’s main function is secretory. It produces a thin, slightly alkaline fluid that mixes with sperm from the testes and fluid from the seminal vesicles to form semen. This prostatic fluid contains enzymes, zinc, citric acid, and proteins that help sperm survive and function after ejaculation.

One of the most important proteins in prostatic fluid is prostate-specific antigen, or PSA. Despite its fame as a cancer screening marker, PSA’s actual biological role is straightforward: it liquefies semen. When semen first leaves the body, it forms a gel-like coagulum. PSA is a serine protease that breaks down the proteins responsible for that coagulation, called semenogelins. As PSA degrades these proteins, semen becomes liquid, freeing sperm to swim. Researchers have shown that specifically blocking PSA activity prevents semen from liquefying and significantly reduces sperm motility, confirming that PSA is the key enzyme driving this process.³

The prostate also contributes to urinary control. Smooth muscle fibers within the gland help regulate the flow of urine and prevent semen from entering the bladder during ejaculation, a process called antegrade ejaculation. When the prostate enlarges or is surgically removed, these functions can be disrupted.

How Hormones Drive Prostate Growth

The prostate is one of the most hormone-sensitive organs in the body. Its development, maintenance, and pathological growth are all driven by androgens, particularly dihydrotestosterone (DHT). Testosterone, produced mainly in the testes, gets converted into DHT inside prostate cells by an enzyme called 5-alpha reductase. DHT is the more potent form and is what actually drives prostate tissue to grow and differentiate.⁴

This relationship has been confirmed by studying men born with a genetic deficiency in 5-alpha reductase type 2. These men produce normal testosterone but cannot convert it efficiently to DHT. The result is a very small or absent prostate, demonstrating that DHT is essential for the gland to develop in the first place. During fetal development, DHT triggers the formation of the prostatic buds that eventually grow into the branching ductal system of the adult gland.

The trouble is that DHT does not stop working after puberty. While it plays a beneficial role during development, ongoing DHT activity in adulthood can fuel unwanted prostate growth. This dual nature of DHT, helpful early in life and potentially harmful later, is central to understanding benign prostatic hyperplasia.⁵

Benign Prostatic Hyperplasia

Benign prostatic hyperplasia, or BPH, is the most common prostate condition. It involves a non-cancerous enlargement of the gland that becomes increasingly likely as men age. By the time men reach their sixties, a majority have at least some degree of prostatic enlargement, and the prevalence continues to climb from there.

BPH develops when both the stromal (supportive tissue) and epithelial (glandular) cells in the transition zone begin to proliferate. This growth is thought to be influenced by sex hormones and chronic low-grade inflammation.⁶ Additional risk factors include genetics, growth factors, and lifestyle.⁷

Because the transition zone surrounds the urethra, even modest enlargement can produce bothersome urinary symptoms: a weak stream, difficulty starting or stopping urination, frequent nighttime trips to the bathroom, and a feeling that the bladder never fully empties. These symptoms are collectively called lower urinary tract symptoms, and they are the main reason BPH sends men to a doctor.

Treatment often starts with medications. Alpha-blockers relax the smooth muscle around the prostate and bladder neck to improve urine flow, while 5-alpha reductase inhibitors (5-ARIs) block the conversion of testosterone to DHT and can actually shrink the gland over time. Starting a 5-ARI earlier rather than later appears to matter. In one analysis of more than 8,600 men already taking alpha-blockers, those who added a 5-ARI within the first month were less likely to experience clinical progression, acute urinary retention, or need for surgery compared to men who waited longer.⁸ When medications are not enough, surgical procedures ranging from minimally invasive techniques to traditional resection can open up the blocked urinary channel.

Prostatitis

Prostatitis, or inflammation of the prostate, is the most common prostate diagnosis in men under 50. It is classified into four categories by the National Institutes of Health, and the breakdown matters because the categories differ sharply in cause and treatment.

Categories I and II are bacterial infections. Acute bacterial prostatitis (category I) hits hard with fever, chills, and severe urinary pain, and generally responds well to antibiotics. Chronic bacterial prostatitis (category II) involves recurring infections that are harder to shake but still respond to antimicrobial treatment.⁹

The overwhelming majority of prostatitis cases, however, fall into category III: chronic prostatitis or chronic pelvic pain syndrome. This accounts for roughly 90 to 95 percent of all prostatitis diagnoses, and its cause remains unknown. Patients experience a mix of pelvic pain, urinary difficulty, and ejaculatory discomfort, but no clear infection is found and no single therapy reliably helps.¹⁰ Category IV is asymptomatic inflammation discovered incidentally during testing for something else. It generally does not require treatment.

The frustration of chronic pelvic pain syndrome is that it often leads to repeated rounds of antibiotics that do not help, because there is no bacterial target. Current thinking focuses on nerve sensitization, pelvic floor dysfunction, and immune dysregulation as possible contributors, and treatment has shifted toward multimodal approaches including physical therapy, anti-inflammatory agents, and stress management rather than antibiotics alone.

Prostate Cancer

Prostate cancer is the most commonly diagnosed non-skin cancer in men in many countries. Most prostate cancers arise in the peripheral zone and grow slowly enough that many men with the disease will die of something else entirely. The challenge has always been distinguishing the slow-growing cancers that can safely be monitored from the aggressive ones that need treatment.

Genetics plays a meaningful role in risk. Around 170 susceptibility loci have been identified in European populations so far, and men in the top 1 percent of genetic risk profiles face roughly a five- to six-fold increase in their likelihood of developing the disease compared to controls. Collectively, known genetic variants explain about 38 percent of the familial risk, meaning there is still much to uncover.¹¹ Family history remains one of the strongest individual risk factors, alongside age and African ancestry.

Treatment options for localized prostate cancer include active surveillance (monitoring without immediate treatment), surgery (radical prostatectomy), and radiation therapy. A systematic review comparing patient-reported outcomes across these approaches found that radiation therapy was associated with greater impairment of bowel function and voiding symptoms, while surgery was more likely to affect sexual and urinary continence.¹² None of the treatment approaches significantly affected overall mental or physical quality of life in the long run, which underscores that the choice often comes down to which side effects a patient most wants to avoid.

For men on active surveillance compared directly with external-beam radiation, the picture is clearer in the short term. A prospective study found that men receiving radiation had significantly worse bowel function at both one and two years post-treatment, with over half experiencing a decline in bowel function at the one-year mark compared to fewer than one in five of those under surveillance.¹³

What Happens After Prostate Surgery

Radical prostatectomy removes the entire gland, and that comes with unavoidable consequences because of the prostate’s location and connections. All men lose the ability to ejaculate, because the organ that produced the ejaculatory fluid is gone. Orgasm quality is diminished for many, even when sensation is partially preserved. Erectile dysfunction is immediate and recovery is slow, often taking up to 18 months. Medications like PDE-5 inhibitors (the class that includes sildenafil) are initially ineffective and take time to start working as nerves recover. Younger men who have bilateral nerve-sparing surgery tend to recover the best.¹⁴

Urinary incontinence is another common aftereffect, ranging from occasional stress leakage to more persistent issues. Most men see gradual improvement over months, but a minority deal with lasting incontinence that may require further intervention. These functional trade-offs are a major reason active surveillance has become the preferred approach for many low-risk prostate cancers: if the tumor is unlikely to cause harm in a man’s lifetime, avoiding treatment also avoids its side effects.

PSA Screening and Its Limits

PSA, the same enzyme that liquefies semen, leaks into the bloodstream in small amounts. Elevated blood PSA levels can signal prostate cancer, but the test is far from straightforward. A meta-analysis pooling data from more than 14,000 symptomatic patients found that PSA had high sensitivity (about 93 percent) but very low specificity (about 20 percent) for detecting prostate cancer.¹⁵ In plain terms, an elevated PSA catches most cancers but also flags many men who do not have cancer at all. BPH, prostatitis, urinary tract infections, and even vigorous exercise can raise PSA.

This specificity problem has driven the search for better markers. Refinements like PSA density (dividing PSA by prostate volume) and the ratio of free to total PSA offer some improvement.¹⁶ Multiparametric MRI has also become a standard part of the diagnostic workup. One recent study found that PSA density was the strongest predictor of clinically significant cancer in men with ambiguous MRI findings, and that in selected low-risk groups the rate of clinically significant cancer was rare enough that biopsy could potentially be avoided, with specificity reaching up to 90 percent.¹⁷

Urine-Based Biomarkers

One of the more promising directions in prostate diagnostics is the development of urine-based tests. These are appealing because they are non-invasive and can be collected at home in some cases. A systematic review of urine biomarkers found that tests not requiring a digital rectal exam beforehand, such as the Exosome Dx Prostate IntelliScore and Protexam PSM/PSU, performed well at detecting clinically significant cancer. Among tests using urine samples collected after a digital rectal exam, the MyProstateScore test showed the strongest results.¹⁸

Another approach uses gene expression panels from exosomes, tiny vesicles shed by cells into urine. In a racially diverse group of patients, a two-gene panel combined with standard clinical information improved the prediction of high-grade cancer at diagnosis compared with standard information alone.¹⁹ The goal of these tools is not to replace PSA or biopsy outright, but to help clinicians and patients make better-informed decisions about who truly needs a biopsy and who can safely avoid one.

Metabolic Syndrome and Prostate Health

A growing body of evidence links metabolic syndrome, the cluster of conditions including insulin resistance, obesity, high blood pressure, and abnormal cholesterol levels, to worse prostate outcomes. Multiple clinical and experimental studies have found that these metabolic factors can worsen prostatic enlargement and bladder obstruction in men with BPH.²⁰

The proposed mechanism centers on chronic inflammation. Central obesity drives inflammatory signaling from fat tissue, which activates immune responses in the prostate itself. Lower levels of HDL cholesterol may amplify this inflammation further, contributing to tissue remodeling and gland enlargement.²¹ The overlap in molecular pathways between metabolic syndrome and BPH has led some researchers to suggest that treating metabolic factors like insulin resistance and obesity could benefit the prostate as well.²²

Emerging research has also found that the microbiome, the community of bacteria living in and around the prostate, may play a role in prostate inflammation linked to both benign conditions and cancer.²³ This is still early-stage science, but it opens up the possibility that managing inflammation through diet, metabolic health, and possibly even the microbiome could influence prostate disease trajectories.

The Female Prostate and Evolutionary Origins

Despite popular belief, the prostate is not exclusive to males. Skene’s glands, located near the female urethra, are now recognized as a female prostate. Immunohistochemical studies have found that the same proteins expressed in the male prostate, including human protein 1, are distributed in the same way in Skene’s glands, providing evidence that these structures are genuine functional homologs rather than vestigial remnants.²⁴ This functional similarity between the male and female prostate has been demonstrated in both humans and rodents and persists across the lifespan.²⁵

From an evolutionary standpoint, the prostate appears to be an ancient mammalian feature. One evolutionary analysis concluded that the prostate and breast appeared at the same time, roughly 65 million years ago, with the rise of mammals. All male mammals have a prostate, though the accompanying seminal vesicles vary. The seminal vesicles appear to be diet-dependent: species that are primarily carnivorous tend to lack them.²⁶ Studies of neotropical bats confirm this pattern, showing species with well-developed prostates but no seminal vesicles, along with considerable variation in prostatic structure across bat families.²⁷ The prostate, it turns out, is one of the most evolutionarily conserved features of the male mammalian reproductive tract, even as the organs around it have shifted considerably across species.